Liaoning Chengda Biotechnology Co Ltd
SSE:688739

Watchlist Manager
Liaoning Chengda Biotechnology Co Ltd Logo
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Watchlist
Price: 26.71 CNY -4.02% Market Closed
Market Cap: 4.9B CNY
Have any thoughts about
Liaoning Chengda Biotechnology Co Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-1.7
Current
0
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.7
=
Enterprise Value
-735.7m CNY
/
EBIT
433m CNY
All Countries
Close
EBIT Growth
CN
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Average EV/EBIT: 22.5
Negative Multiple: -1.7
18%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.9
2-Years Forward
EV/EBIT
-0.8
3-Years Forward
EV/EBIT
-1.2

See Also

Discover More